72 related articles for article (PubMed ID: 25397550)
1. Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study.
Spagnuolo V; Galli L; Bigoloni A; Nozza S; Monforte Ad; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Lazzarin A; Castagna A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19806. PubMed ID: 25397550
[TBL] [Abstract][Full Text] [Related]
2. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Castagna A; Spagnuolo V; Galli L; Vinci C; Nozza S; Carini E; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Lazzarin A;
AIDS; 2014 Sep; 28(15):2269-79. PubMed ID: 25058680
[TBL] [Abstract][Full Text] [Related]
3. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
[TBL] [Abstract][Full Text] [Related]
4. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19808. PubMed ID: 25397552
[TBL] [Abstract][Full Text] [Related]
5. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.
Antinori A; Arribas J; Fehr J; Girard PM; Horban A; Hill A; van Delft Y; Moecklinghoff C; Hill A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19525. PubMed ID: 25394034
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication.
Pinnetti C; Lorenzini P; Cozzi-Lepri A; Sandrine O; Tommasi C; Zaccarelli M; Perno CF; Capobianchi MR; Girardi E; Antinori A; Ammassari A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19809. PubMed ID: 25397553
[TBL] [Abstract][Full Text] [Related]
7. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
[TBL] [Abstract][Full Text] [Related]
8. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
9. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Palacios R; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
J Antimicrob Chemother; 2017 Jan; 72(1):246-253. PubMed ID: 27629070
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
Katlama C; Valantin MA; Algarte-Genin M; Duvivier C; Lambert-Niclot S; Girard PM; Molina JM; Hoen B; Pakianather S; Peytavin G; Marcelin AG; Flandre P
AIDS; 2010 Sep; 24(15):2365-74. PubMed ID: 20802297
[TBL] [Abstract][Full Text] [Related]
11. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials.
Arribas J; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
J Int AIDS Soc; 2014; 17(4 Suppl 3):19788. PubMed ID: 25397532
[TBL] [Abstract][Full Text] [Related]
13. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
[TBL] [Abstract][Full Text] [Related]
14. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.
Clumeck N; Rieger A; Banhegyi D; Schmidt W; Hill A; Van Delft Y; Moecklinghoff C; Arribas J
J Antimicrob Chemother; 2011 Aug; 66(8):1878-85. PubMed ID: 21652619
[TBL] [Abstract][Full Text] [Related]
15. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
[TBL] [Abstract][Full Text] [Related]
16. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.
Valantin MA; Lambert-Niclot S; Flandre P; Morand-Joubert L; Cabiè A; Meynard JL; Ponscarme D; Ajana F; Slama L; Curjol A; Cuzin L; Schneider L; Taburet AM; Marcelin AG; Katlama C;
J Antimicrob Chemother; 2012 Mar; 67(3):691-5. PubMed ID: 22160145
[TBL] [Abstract][Full Text] [Related]
18. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
19. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
